175 Estradiol and other sex-hormone dynamics in menstrual migraine 8 Table 3. Pathway analysis evaluating the differences in hormonal subsets between patients with migraine and healthy controls. Subset p-value Statistic Expected SD No. of variables in subset Estradiol decline day 8-14 0·02 11·73 2·52 3·38 1 Estradiol peak (day 8) 0·04 9·8 2·44 3·30 1 FSH/Estradiol ratio 0·14 4·26 2·49 1·89 7 Progesterone decline day 8-14 0·17 4·77 2·49 3·28 1 Testosterone 0·21 3·70 2·48 2·62 7 FSH 0·24 3·36 2·49 2·00 7 Testosterone/Estradiol ratio 0·24 3·35 2·48 2·60 7 Declines luteala 0·24 3·20 2·48 1·63 12 All declinesb 0·26 3·10 2·48 1·63 14 Estradiol day 8, 10, 12, 14 0·35 2·65 2·48 2·09 4 Estradiol 0·30 3·08 2·60 2·23 7 LH decline day 1-3 0·47 1·75 2·47 2·81 2 Androsteendion 0·53 1·75 2·48 2·19 7 17-OHP 0·56 1·75 2·47 1·99 7 Cycle hormones day 8, 10, 12, 14 0·56 1·84 2·47 1·74 16 LH/Progesterone ratio 0·56 2·27 2·35 0·77 7 LH/FSH ratio 0·58 1·71 2·46 1·94 7 Progesterone 0·65 1·42 2·46 1·99 7 Cycle hormones 0·70 1·66 2·47 1·40 28 Estradiol/Progesteron ratio 0·70 2·07 2·44 0·67 7 Androgens 0·72 1·51 2·49 1·54 35 Progesterone/Estradiol ratio 0·74 1·19 2·46 1·96 7 DHEA and DHEA-S 0·77 1·04 2·48 2·16 14 SHBG 0·81 0·50 2·47 2·93 7 LH 0·84 1·03 2·47 1·81 7 DHT 0·92 0·44 2·48 2·64 7 a Declines in the late luteal phase (day 8, 10, 12, 14) consisted out of estradiol and progesterone, including the subsections. b All declines consisted out of estradiol and progesterone in the late luteal phase, and the LH decline from days 1-3 after ovulation. c Declines were calculated as the difference in plasma levels between day 14 and day 8 during the late luteal phase. Additionally, subsections were calculated for each hormone, using intervals between specific days: day 14–12, day 14–10, day 12–10, day 12–8, and day 10–8.
RkJQdWJsaXNoZXIy MjY0ODMw